Improving oestrogen metabolism is of benefit to women who suffer from oestrogen-dominant conditions such as endometriosis, premenstrual syndrome and uterine fibroid tumors.
“Are you aware that 80% of breast cancer occur in women with no family history? Research has shown that an increased lifetime exposure to oestrogen is a strong risk factor in the development of breast cancer.”
DNA Oestrogen reports on the following areas:
Phase 1 detoxification
Phase 2 detoxification
Personal risk factors associated with HRT, oral contraceptives, bio-identical supplementation and in vitro fertilisation
DNA Oestrogen tests for gene variants shown to have an impact on how oestrogen is metabolised and therefore may help individuals lessen the risk for developing breast cancer.
Knowledge of individual genetic variations associated with changes in key biological areas that affect mental health can be used to determine strategies for prevention of mental health diseases. Weaknesses in these areas, together with environmental factors, increase risk for development of disorders related to mental health.
“DNA Mind analyses 30 genes shown to have significant associations with key mental health disorders.”
DNA Mind reports on associations in the following areas:
Neurodegenerative disorders – mild cognitive decline and late onset Alzheimer’s disease.
Addictive behaviour – risk of alcohol, nicotine, cannabis & opioid dependence, psychosis response from cannabis use and eating disorders (binge eating).
Genetic variations involved in key biological processes that contribute towards the risk of development of mental health disorders may give insight to the prevention, diagnosis and treatment of disease.
DNA Health® tests for genetic variations that are known to have a significant effect on health and susceptability to chronic diseases such as osteoporosis, cardiovascular disease and diabetes amongst others Research has shown that individualised diet and lifestyle choices do have a significant effect on the expression of these genes – but this also depends on early detection and appropriate intervention.
DNA Health® reports on genes involved in the following areas:
Food responsiveness, such as sensitivities to lactose, caffeine and salt intake
Food allergies and food sensitivites are abnormal responses to a food component triggered by the immune system in the form of immunoglobulins (IgE, IgG, IgA, IgM), representing either an immediate or delayed immune response. Elevated IgA antibodies to specific food proteins are believed to be a food sensitivity-related condition.
IgA antibodies are, like IgG antibodies, a part of the body’s immune system. They are mostly present in bodily secretions such as saliva and mucosa (secretory IgA), but are also secreted in the blood. Whilst a clear role for IgA towards food antigens remains unknown, high serum levels of IgA to specific food proteins are believed to be a possible indicator of antigen exposure and mucosal damage. Thus, elevated serum IgA towards specific food proteins may possibly suggest a loss of oral tolerance to the foods of concern. The only food-specific IgA antigen that was been established as an indicator of antigen-exposure is the gluten-related anti-gliadin IgA.
Small Intestinal Bacterial Overgrowth (SIBO) occurs when bacteria appear in the normally more sterile small intestine and begin to colonize.
Hydrogen (H2) and methane (CH4) gasses are produced in the digestive system primarily only by the bacterial fermentation of carbohydrates (sugars, starches or vegetable fibers). The generation of H2 and/or CH4 will result in the absorption of some of these gases into the blood stream from the site of their production, and they will appear in the expired air. If either of the gases appear in the expired air, it is usually a signal that carbohydrates or carbohydrate fragments have been exposed to bacteria, permitting such fermentation to take place and that SIBO can be suspected.
This SIBO breath collection kit comes with either Glucose or Lactulose as a substrate.
Studies have indicated that potentially up to 80% of patients with IBS may in fact have SIBO which this Hydrogen /Methane breath test can easily and non-invasively help determine.
The GI360 Essentials Profile is an innovative, comprehensive and clinically-applicable stool profile, utilizing multiplex PCR molecular technology coupled with growth-based culture and ID by MALDI-TOF, sensitive biochemical assays and microscopy to detect and assess the status of pathogens, viruses, parasites and bacteria that may be contributing to acute or chronic gastrointestinal symptoms and disease.
Microbiome Abundance and Diversity is a gut microbiota DNA analysis tool that identifies and characterizes the abundance and diversity of more than 45 targeted analytes that peer-reviewed research has shown to contribute to dysbiosis and other chronic disease states.
The GI360 Essentials can identify the presence of pathogenic viruses, bacteria, and parasites using multiplexed, real-time PCR. Viruses are the primary cause of acute diarrhea, and the least commonly tested. The identification of pathogenic bacteria, viruses and parasites improves treatment strategies and patient outcomes.
The Dysbiosis Index (DI) is a calculation with scores from 1 to 5 based on the overall bacterial abundance and profile within the patient’s sample as compared to a reference population. Values above 2 indicate a microbiota profile that differs from the defined normobiotic reference population (i.e., dysbiosis). The higher the DI above 2, the more the sample is considered to deviate from normobiosis.
GI Effects is an innovative stool test measuring premier biomarkers of gastrointestinal function, providing valuable clinical insight into digestive performance, gut inflammation, and the gut microbiome — areas affecting not only GI health, but overall health as well.
Functional testing can help uncover the root cause of many chronic conditions that often frustrate both physician and patient. The scope of the biomarkers on the GI Effects Stool Profile provides comprehensive information to the clinician for the development of strategic interventions. As identified functional imbalances and inadequacies become more normalized through targeted dietary, lifestyle, and supplementation therapeutics, intractable symptoms often improve for many patients.
• Quick overview and synthesis of results reflecting the status of the 3 key functions of gut health arranged in the “DIG” format: digestion, inflammation, and the gut microbiome
• Therapeutic support options to serve as potential treatment ideas
• A Commensal Balance Infographic, total & relative – Designed to provide a more precise view of an individual patient’s commensal bacteria (PCR) results relative to a spectrum of healthy and unhealthy commensal patterns.
• Including Inflammation-Associated Dysbiosis score & Methane Dysbiosis Score (Immune Suppression) to help guide therapy
• Clinical Association Charts – See how patient results compare to commensal bacteria (PCR) and biomarker patterns seen in patients with specific clinical conditions, such as IBS, IBD, Metabolic Syndrome, Chronic Fatigue, Autoimmune dysfunction, Type 2 Diabetes, High Blood Pressure and Mood Disorders.
Correlations are now evident between many disease processes and patterns of microbiome dysbiosis in both gut dysfunction and extra-intestinal disorders.
The Gastrointestinal Microbial Assay Plus (GI-MAP) is an innovative clinical tool that measures gastrointestinal microbiota DNA from a single stool sample with state of the art, quantitative polymerase chain reaction (qPCR) technology.
The GI-MAP was designed to detect microbes that may be disturbing normal microbial balance or contributing to illness as well as indicators of digestion, absorption, inflammation, and immune function. With a culture based test it is not possible to measure strict anaerobes, viruses or virulence factors.
The GI-MAP’s accuracy and reliability allows personalized protocols to address gut dysfunction based on which infections are urgent, which areas of the gut are already optimized, and which areas should be addressed after an infection is resolved. Additionally, the quantification of identified micro-organisms offers a remarkable ability to see how treatment modalities are working because a retest after treatment can show whether a parasite has resolved, dysbiosis has improved, and more.
• Autoimmune molecular mimicry (if caused by pathogens)
• Foodborne illness
• Gastroenteritis (if it has viral causes)
• Gut dysbiosis
• Inflammation• Suspected bacterial, parasitic or viral pathogenesis (incl. detection of antibiotic resistant bacteria)
The Organic Acids Test (OAT) offers a comprehensive metabolic snapshot of a patient’s overall health with over 70 markers. It provides an accurate evaluation of intestinal yeast and bacteria. Abnormally high levels of these microorganisms can cause or worsen behavior disorders, hyperactivity, movement disorders, fatigue and immune function. Many people with chronic illnesses and neurological disorders often excrete several abnormal organic acids in their urine. The cause of these high levels could include oral antibiotic use, high sugar diets, immune deficiencies, acquired infections, as well as genetic factors.
This Organic Acids Test also includes markers for vitamin and mineral levels, oxidative stress, neurotransmitter levels, and is the only OAT to include markers for oxalates, which are highly correlated with many chronic illnesses.
If abnormalities are detected using the OAT, treatments can include supplements, such as vitamins and antioxidants, or dietary modification. Upon treatment, patients and practitioners have reported significant improvement such as decreased fatigue, regular bowel function, increased energy and alertness, increased concentration, improved verbal skills, less hyperactivity, and decreased abdominal pain. The OAT is strongly recommended as the initial screening test.
The Organix Comprehensive test is a nutritional test providing insights into organic acids and a view into the body’s cellular metabolic processes. Additionally, children’s reference ranges are designed to provide more accurate pediatric nutritional evaluations. Identifying metabolic blocks that can be treated nutritionally allows individual tailoring of interventions that maximize patient responses and lead to improved patient outcomes.
Organic acids are metabolic intermediates that are produced in pathways of central energy production, detoxification, neurotransmitter breakdown, or intestinal microbial activity. Marked accumulation of specific organic acids detected in urine often signals a metabolic inhibition or block. The metabolic block may be due to a nutrient deficiency, an inherited enzyme deficit, toxic build-up or drug effect. Several of the biomarkers are markers of intestinal bacterial or yeast overgrowth.
The LC/MS-MS test method – which is also used to screen newborns for metabolic disorders – requires very little sample preparation and processing. This technology provides more stability, accuracy, and sensitivity in measuring organic acids at low levels for optimum test results.
Only a single urine collection is required, which is easy for patients, leading to increased patient compliance.